Inventor · disambiguated record
Christen M. Anderson
Also filed as: ANDERSON CHRISTEN · ANDERSON CHRISTEN M · ANDERSON CHRISTEN MARIE
13 granted patents·16 pending applications·77 citations·filing 1998–2023
90Inventor score
Top patents by PatentIndex Score
29 records- 0183US8999970B2Administration of an anti-obesity compound to individuals with renal impairmentANDERSON CHRISTEN M·Filed 2011·Granted Apr 7, 2015·9 cites·28 claims
- 0282US8394765B2Methods of treating obesity with two different anti-obesity agentsROTH JONATHAN D·Filed 2007·Granted Mar 12, 2013·5 cites·33 claims
- 0382US6140067AIndicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitusMITOKOR·Filed 1999·Granted Oct 31, 2000·39 cites·140 claims
- 0479US9770455B2Administration of an anti-obesity compound to individuals with renal impairmentARENA PHARM INC·Filed 2017·Granted Sep 26, 2017·2 cites·6 claims
- 0579US6653094B2Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitusMITOKOR INC·Filed 2001·Granted Nov 25, 2003·13 cites·8 claims
- 0679US6280966B1Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitusMITOKOR·Filed 2000·Granted Aug 28, 2001·4 cites·16 claims
- 0772US2024122886A1Methods of treatmentARENA PHARM INC·Filed 2023·Application pending·0 cites
- 0870US8946149B2Use of exendin and analogs thereof to delay or prevent cardiac remodelingANDERSON CHRISTEN·Filed 2006·Granted Feb 3, 2015·4 cites·24 claims
- 0963US6906175B2Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor.MIGENIX CORP·Filed 2001·Granted Jun 14, 2005·1 cites·10 claims
- 1055US2007021336A1Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosisANDERSON CHRISTEN·Filed 2005·Application pending·0 cites
- 1154US2009264352A1Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosisANDERSON CHRISTEN·Filed 2009·Application pending·0 cites
- 1251US7001729B2Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays thereforMIGENIX CORP·Filed 2001·Granted Feb 21, 2006·0 cites·22 claims
- 1351US6906174B2Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays thereforMIGENIX CORP·Filed 2001·Granted Jun 14, 2005·0 cites·10 claims
- 1451US6902908B2Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays thereforMIGENIX CORP·Filed 2001·Granted Jun 7, 2005·0 cites·35 claims
- 1551US6887670B2Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays thereforMIGENIX CORP·Filed 2001·Granted May 3, 2005·0 cites·11 claims
- 1651US2004241801A1Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays thereforMITOKOR INC·Filed 2004·Application pending·0 cites
- 1750US2003235812A1Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitusMITOKOR·Filed 2003·Application pending·0 cites
- 1850US2020368190A1Methods of treatmentARENA PHARM INC·Filed 2018·Application pending·0 cites
- 1949US2002004043A1Cellular and animal models for diseases associated with altered mitochondrial functionFiled 2001·Application pending·0 cites
- 2047US2010323955A1Methods for treating obesity and obesity related diseases and disordersAMYLIN PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 2146US2015196567A1Administration of an anti-obesity compound to individuals with renal impairmentARENA PHARM INC·Filed 2015·Application pending·0 cites
- 2246US2003026781A1Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetesMITOKOR·Filed 2002·Application pending·0 cites
- 2342US2009156474A1Methods for treating obesity and obesity related diseases and disordersAMYLIN PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 2441US2013267500A15-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine levelANDERSON CHRISTEN M·Filed 2011·Application pending·0 cites
- 2540US2002049176A1Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discoveryFiled 2001·Application pending·0 cites
- 2640US2002082193A1Inhibition of mitochondrial calcium/sodium antiporterMITOKOR·Filed 2001·Application pending·0 cites
- 2739US2004072739A1Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetesFiled 2001·Application pending·0 cites
- 2830US6906173B2Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays thereforMIGENIX CORP·Filed 1998·Granted Jun 14, 2005·0 cites·12 claims
- 2929US2002106354A1Cellular and animal models for diseases associated with altered mitochondrial functionFiled 1999·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →